Select a community
Mood Conditions including Depression, Anxiety, Bipolar, OCD, and PTSD
Find out more about the PatientsLikeMe
Mood Conditions Community
Home > Community Treatment Reports > Rizatriptan Treatment Report
What is Rizatriptan?

Rizatriptan is an antimigraine agent available under the brand names Maxalt-MLT®; Maxalt®. It is used in the treatment of acute treatment of migraine with or without aura.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Migraine 11 4
Headaches 3 2
Other 2 0
Tension Headaches 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
1 20%
Mild
2 40%
None
2 40%

Most commonly reported side effects

Drowsiness
3 60%
Tingling in face
1 20%
Jaw pain
1 20%
  • Mild
  • Moderate
  • Severe

Dosages

  10mg as needed 5 mg as needed 5mg as needed 10 mg daily
  10 Number of Patients: 10 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2  

Stop Reasons

Why Patients Stopped Taking Rizatriptan (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice
2 50% Doctor's advice: 50%
Other
1 25% Other: 25%
Not indicated
1 25% Not indicated: 25%

See all 4 patients who’ve stopped taking Rizatriptan

Duration See details about how long patients take this treatment ▼

Currently Taking Rizatriptan

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
2
3
1
3

Stopped Taking Rizatriptan

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
0
0
0
2

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
2 40%
Usually
1 20%
Sometimes
2 40%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
1 20%
A little
1 20%
Not at all
3 60%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
2 40%
< $25
1 20%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 23, 2009.